NGD 94-1 blocker of the D4 dopamine receptor: Began Phase I safety trial using escalating doses in 50 normal volunteers

Neurogen Corp. (NRGN), Branford, Conn. Product: NGD 94-1 blocker of the D4 dopamine receptor Indication: Schizophrenia Status: Began Phase I safety trial using escalating doses in 50 normal volunteers...